Alumni

Alumni
QuickFire
Challenge Winner
At Ab Initio, we are using a proprietary directed evolution engineering technology to
Alumni
Achelois’ mission is to develop effective and nontoxic therapeutics to inhibit tumors, and
Alumni
Convoy’s technology platform focuses on solving major unmet needs in aesthetics and
Alumni
Adicet is developing a novell cell therapy platform.
Alumni
Development of targeted nanoparticle medicines for the treatment of cancer and other
Alumni
Batu Biologics is an immunotherapy company dedicated to developing therapeutics that
Alumni
QuickFire
Challenge Winner
Chestnut Pharmaceuticals Inc. is seeking a cure for metastatic cancers. The company is
Alumni
Antibody therapeutics for the immune synapse.
Alumni
Delivering the promise of precision medicine by matching cancer patients with optimal
Alumni
QuickFire
Challenge Winner
Cyteir is revolutionizing the concept of DNA damage and repair. Conventional therapies
Alumni
DNAtrix is a privately held biotech company focusing on the development of oncolytic
Alumni
Dragonfly Therapeutics develops novel first-in-class therapeutics targeted at Natural
Alumni
EpicentRx, a clinical stage biotechnology company, is at the forefront of the rapidly
Alumni
Forge Therapeutics, Inc is an early stage biotechnology company discovering and developing